Actinium-225 (225Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2018
At a glance
- Drugs Lintuzumab Ac-225 (Primary) ; Plerixafor; Spironolactone
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Preliminary data of the interim analysis (n=18) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 03 Dec 2018 Results from the second cohort of the patients (n=27) presented in a media release.
- 03 Dec 2018 According to a Actinium Pharmaceuticals media release, data from the second cohort of this study (n=27) were presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition.